Your daily dose of the clinical news you may have missed.

Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.

The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.

Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.

The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.